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U.S. Strategy for Rapid Scale-Up of ARV
Treatment: Advocacy Issues and Concerns
Policy Background and Report from a Consultation
Landmark legislation approved in 2003 expandingthe U.S. response to the global AIDS crisis
requires the President to establish a comprehensive,
integrated, five-year strategy “that strengthens the
capacity of the United States to be an effective leader
of the international campaign against HIV/AIDS.”1
The government-wide strategy is intended to guide
policies and programs to meet specific targets for
prevention, treatment, and care and support.
A consultation on “U.S. Strategy for Rapid Scale-Up
of ARV Treatment: Advocacy Issues and Concerns”
was held in December 2004 to provide an opportunity
for global AIDS advocates, including representatives
of operational, research, and policy organizations, to
reflect on the policies needed to meet the legally
mandated goal for expanding access to antiretroviral
(ARV) treatment. The consultation included an
examination of lessons gleaned to date from current
ARV treatment programs, an overview of the World
Health Organization’s treatment initiative, dialogue
with selected policymakers, and deliberations to
identify strategic priorities for advocacy.
This report first provides background on international
developments concerning ARV drugs, and on U.S.
policy on the issue.  Next, it summarizes the presenta-
tions by a panel of representatives from organizations
that are providing ARV treatment in developing
countries, and another presentation on the World
Health Organization’s “3 by 5” Campaign. Finally, it
outlines the key elements identified by consultation
participants as essential for successful scale-up of
ARV treatment.
1 Public Law 108-25
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I.  The Treatment Imperative
therapy.  Without access to ARVs, virtually all of those
six million will die before 2005.3 By December 2002,
only 300,000 people in resource-limited settings had
access to these life-saving medicines, with fully half of
those living in Brazil. In sub-Saharan Africa, only
50,000 out of the 4.1 million in need received ARV
therapy in 2002.
“The AIDS treatment gap is a global public
health emergency. We must change the way we
think and change the way we act.   Business as
usual means watching thousands of people die
every single day.”
—Dr. Lee Jong-Wook, WHO Director-General
United Nations General Assembly, New York
22 September 2003
This gap has fueled efforts by advocates to promote
the production and export of generic drugs, and to
convince governments and the private sector to ensure
affordable access to essential medicines.   While
important progress has been made in reducing prices,
drugs remain generally unavailable for most of those
who need them.
U.S. Law and Antiretroviral
Treatment
It is against this backdrop that the Bush Administration
and the U.S. Congress moved in record time to pro-
mulgate the “United States Leadership Against HIV/
AIDS, Tuberculosis, and Malaria Act of 2003,” a
comprehensive new policy for U.S. global AIDS
programs. The new policy authorized $3 billion per
year for five years and created a new ambassadorial
level position of Global AIDS Coordinator, to be
housed in the Office of the Secretary of State.
The new law includes non-binding “sense of Con-
gress” targets for expanded treatment access, calling
for programs to reach 500,000 individuals by the end
of fiscal year (FY) 2004, 1 million by FY 2005, and
“The time has come to put all the pieces
together. Plans have been made. Needs are
clear. Solutions are available. Leadership is
gathering momentum. Now act!”
—Dr. Peter Piot
Executive Director, UNAIDS
Report on the Global HIV/AIDS Epidemic,
2002
The past three years have witnessed a turning point in
the global response to the HIV/AIDS epidemic.  Since
2001, world leaders have committed themselves to
achieving concrete objectives by specific deadlines,
prices for ARV drugs have been dramatically reduced,
and a new global institution to mobilize and disburse
additional resources – the Global Fund to Fight AIDS,
Tuberculosis, and Malaria (GFATM) – has been
established.
This more robust global response to HIV/AIDS was
prompted, in part, by the unforeseen magnitude of the
epidemic. UNAIDS reported in July 2002 that “The
scale of the AIDS crisis now outstrips even the worst-
case scenarios of a decade ago.”2  That report found
that an estimated 40 million adults and children in
developing countries were living with HIV/AIDS and
the rate of infection was continuing to increase, even
in high prevalence countries.  In Zimbabwe, for
example, HIV prevalence among pregnant women
climbed from 29 percent in 1997 to 35 percent in
2000.
For a number of years the policy debate was over
allocating resources to prevention or treatment.  The
consensus that emerged and is now widely accepted is
that prevention and treatment are both part of a
continuum of care and that the availability of treatment
can reinforce prevention efforts.
Currently six million of the 40 million people living
with HIV/AIDS in developing countries need ARV
2 UNAIDS, Report on the Global HIV/AIDS Epidemic, 2002
3 WHO, Treating 3 Million by 2005: Making It Happen, 2003
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2 million by FY 2006.  Starting in FY 2006 through
FY 2008 (when the authorization ends), 55 percent of
the authorized funds must be used for treatment, of
which three-quarters must be for ARV therapy.
The legislation makes expanded access to ARV
treatment one of the cornerstones of U.S. policy. U.S.
funds are authorized for procurement, distribution, and
monitoring of ARV drugs, for strengthening health
care delivery systems, clinical training, care and
treatment, and for treatment for opportunistic infec-
tions.  Food and nutrition support are to be provided,
as a component of ARV therapy, to individuals in-
fected with and affected by HIV/AIDS.
Mechanisms and monitoring to ensure quality control
and the sustainable supply of HIV/AIDS medicines are
authorized in the new law, which also provides for
monitoring to avoid the negative effects of drug
resistance and illegal counterfeiting or black market
sales of AIDS drugs.  The law authorizes evaluation
and surveillance of treatment programs, including
resources for training and capacity development for
improved collection and maintenance of HIV surveil-
lance data.
By late August 2004, the Administration is required to
submit to Congress a report on treatment programs
supported by U.S. government agencies.  In addition,
not later than January 31 each year, the Administration
must report on program activities of the preceding
fiscal year, including an account of the number of
patients receiving treatment for AIDS in each country
that receives U.S. AIDS assistance.
Several pilot programs that include ARV treatment are
authorized by the new law.   The Pilot Program of
Assistance for Children and Families Affected by HIV/
AIDS will provide care and treatment – including ARV
treatment – to children, parents, and caregivers in-
fected with HIV or living with AIDS.  Treatment
programs are to be carried out by community organiza-
tions along with other program activities that address
stigma, the property and inheritance rights of women,
nutrition assistance, children’s education, legal assis-
tance, and counseling.  The Pilot Program on Family
Survival Partnerships will expand treatment through
programs to prevent mother-to-child transmission of
HIV (PMTCT).  The pilot, which will provide care
and treatment for children, parents, and family mem-
bers, will be carried out through grants to local health
organizations and international organizations.
In December 2004, the Centers for Disease Control
and Prevention (CDC) issued a Request for Proposals
for Rapid Expansion of ARV Therapy Programs.  The
proposals are for a five-year period, with $115 million
available for FY 2004.  The proposals were required to
describe plans for clinical care, drug and health
commodities management, laboratory services,
training, community mobilization and behavior
change, and monitoring and evaluation.  The proposals
were also required to describe capacity building
activities aimed at ensuring the sustainability of
treatment programs.
[Note:  The Administration in February 2004 an-
nounced grant awards under this procurement to
Catholic Relief Services, the Elizabeth Glaser Pediat-
ric AIDS Foundation, the Columbia University Mail-
man School of Public Health, and the Harvard School
of Public Health.]
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II.  The On-the-Ground Experience
Because there are relatively few ARV treatment
programs operating in resource-limited settings, there
is a great deal to learn about what is needed to ensure
their effectiveness.  Gaining insights from programs
already underway can help global AIDS advocates
identify key issues for U.S. policies and programs
aimed at meeting the goals for treatment access as
specified in the new law.
Lessons Learned
To learn from those experiences, a panel representing
five different organizations involved in ARV programs
described successes, challenges, and obstacles faced
by their programs.  They highlighted the insights and
lessons that their programs suggest for successful ARV
scale-up.  Discussion following the presentations also
highlighted a number of concerns, including the need
for more gender analysis4 in designing and implement-
ing ARV treatment programs.
The organizations represented were the International
HIV/AIDS Alliance (Alliance), the MTCT-Plus
initiative of the Mailman School of Public Health at
Columbia University (MTCT-Plus), Family Health
International (FHI), Médecins Sans Frontières (MSF),
and the AFL-CIO Solidarity Center.  MTCT-Plus, FHI,
and MSF are currently operating ARV treatment
programs in resource-poor settings.
MSF has the longest experience in operating such
programs.  Having begun in 2000, it now operates
programs in 19 countries, with 10,000 individuals
currently receiving ARV treatment. MTCT-Plus
provides care and treatment to HIV-positive women,
their partners, and children through programs to
prevent transmission of HIV from mothers to their
infants.  The initiative currently operates 12 programs
in eight countries, enrolling 1,092 adults (75 percent
of whom are women) and 511 children. Five percent of
those in the program are receiving ARV treatment.
FHI’s treatment programs began operation in 2003 in
Ghana, Kenya, and Rwanda. As of early December,
2,382 individuals had received comprehensive HIV
care, including treatment for opportunistic infections
and TB.  Nearly 15 percent, or 353 of those receiving
care, have been placed on ARV therapy.
The International HIV/AIDS Alliance is working with
organizations operating ARV treatment programs in
three countries to develop models for community
engagement.  The AFL-CIO Solidarity Center works
with trade unions around the world to respond to the
AIDS epidemic.
[Note: The panelists’ power point presentations can be
found at: http://www.icrw.org/projects/
globalaidsaccountability/resources.htm.]
Common Themes
A number of issues and themes emerged from the
experiences of these organizations in providing ARV
treatment.  These include the following:
The critical importance of community and PLHA
engagement.  Each organization reported that engag-
ing the community and PLHAs is an essential element
of ARV treatment programs, irrespective of the venue
or approach.  Community engagement helps to reduce
HIV/AIDS-related stigma and discrimination, relieves
overburdened public health facilities, and provides
support for care, treatment, and prevention. To be
engaged, the community must have information about
treatment so that it understands the benefits and
challenges involved. This is described as “treatment
literacy.” The experience of these programs confirms
the importance of tapping community resources and
facilitating communication between the community
and clinical staff, PLHA groups, and NGOs.  Programs
are strengthened by mobilizing community resources
for education and advocacy for effective treatment
4 Gender analysis is a form of social analysis that examines the differential impacts on men and women of policies, programs, and legislation that result
from the widely-shared expectations and norms within a society about their respective roles, rights, and responsibilities.
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policies, as well as for planning, implementing, and
evaluating the treatment programs themselves.  MSF
supports advocacy by communities on behalf of
PLHAs to ensure that they can receive appropriate
care without stigma or discrimination.  This means
including advocacy as an integral activity within
treatment programs. MSF also supports community
advocacy for national ARV treatment policies and
programs, which corresponds to its own international
advocacy on access to essential medicines. The
Alliance has found that community engagement
contributes to rebuilding networks, norms, and com-
munity cohesion in areas where HIV/AIDS is unravel-
ing the social fabric of society.
Drug procurement.  Each organization highlighted
difficulties related to drug procurement, particularly
with respect to generic drugs.  MSF primarily uses
generic drugs, consistent with its determination to treat
as many people as possible.  The organization cur-
rently provides first-line ARV treatment for $1 per
patient per day.  MTCT-Plus reported that there is no
guidance at the global level on generics and concurred
with FHI on the complications related to funding and
cost recovery for ARVs, and management of drugs –
including distribution, logistics (transportation and
inventory management), and secure storage to avoid
theft. FHI has used funds from its corporate founda-
tion to underwrite the purchase of ARVs for its current
programs.  MSF has produced in-depth reports and
guidelines related to ARV pricing and procurement.
Funding and donor action.  Financial support for
drug procurement is urgently needed.  The organiza-
tions receiving government funding for their ARV
programs reported that funding for drugs had not been
provided. Support by donors should be aimed at
supporting national governments to develop and
implement national treatment programs through
strengthening public health sectors.  Donor coordina-
tion and fulfillment of agreed-upon commitments are
also of paramount importance.
Stigma.  The involvement of PLHAs in HIV/AIDS
programs helps to overcome the stigma associated
with HIV/AIDS and the discrimination that typically
accompanies stigma.  Stigma prevents individuals
from seeking to learn their HIV status – an essential
step in expanding treatment access.  The programs run
by these organizations foster a supportive clinical
environment as an important ingredient in efforts to
overcome stigma.   FHI used formative research to
assess knowledge and attitudes of health workers and
used the findings to help the workers become aware of
the effects of stigma and how they might be contribut-
ing to it.
Patient selection.  In several programs, patients are
selected for treatment by committees, using pre-
defined eligibility criteria.  In most cases, the commit-
tees include community representatives and clinicians.
Criteria for ARV therapy in MSF programs are a CD4
count of less than 200 for adults and less than 15
percent for children. Eligibility committees in MSF
programs also consider the prior attendance by the
individual at health care programs.  MTCT-Plus
eligibility criteria are based on a combination of CD4
count and WHO’s staging system for HIV infection
and disease. Eligibility includes all patients in clinical
stage IV, those in stage II or III with CD counts below
350, and all patients with CD4 counts below 200. The
experience of these programs suggests that patient
selection criteria and methods will be a key issue in
scaling up, as eligibility committees may not be
practical on a larger scale.
Treatment adherence.  Each program has demon-
strated very high rates of adherence by patients to the
required treatment regimen.  Both MTCT-Plus and
MSF reported adherence rates in excess of 90 percent.
FHI’s programs are built on principles of chronic
disease management, which strengthen the motivation
of the patient and family to maintain wellness and
adhere to treatment requirements.  Chronic disease
management involves active patient and family
participation.  It requires the cultivation of a long-
term, interactive relationship, with patient and health
providers working as a team.  MSF requires or
strongly encourages each patient receiving ARV
therapy to have a partner or assistant to provide
support. The family-centered approach of MTCT-Plus,
with a multidisciplinary team of treatment and care
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providers, contributes to the high adherence rates that
have been evident in its programs.
Service delivery.  The development of standards and
standard operating procedures are essential for estab-
lishing and operating treatment programs in resource-
constrained locations. At the same time, programs
must be adapted to local settings. Based on three years
of experience in providing ARV treatment, MSF
strongly advocates for simplification of treatment as
essential to scaling up programs. The organization is
developing simplified guidelines for ARV treatment
and monitoring.  MSF has found that an important step
toward simplifying treatment is the use of fixed dose
combination drug formulations.
To address the various dimensions of effective treat-
ment, MTCT-Plus fields multidisciplinary teams to
provide comprehensive HIV primary care.  FHI’s
approach is to establish partnerships with govern-
ments, clinical care facilities, PLHA, and community
support groups and NGOs for referral of patients to
necessary services.
Human resources and capacity building.  The
scaling-up of ARV treatment will depend heavily on
the availability of trained individuals to carry out the
programs.  All of the programs have developed re-
sources to guide and support the development and
administration of ARV treatment programs.  The
MTCT-Plus initiative has developed a clinical manual
and a patient data manual, along with training materi-
als on numerous topics.  The Alliance worked with the
World Health Organization and other collaborators
recently to publish the “ARV Toolkit: A Public Health
Approach for Scaling Up Antiretroviral (ARV) Treat-
ment.”  FHI offers a variety of tools, including a
curriculum on HIV/AIDS care and treatment and
guidelines for ARV treatment.
Besides guidelines and training, the programs also
provide ongoing technical assistance and support.
FHI, for example, has established a system for elec-
tronic communications between site-based clinicians
in Rwanda and clinical experts at FHI offices in the
U.S. and the Institute of Tropical Medicine in Bel-
gium.  The system provides support for difficult-to-
manage cases.
Lessons Learned. Scaling-up of ARV treatment
programs should include a close examination of
current projects and certain ARV delivery systems
based in the U.S. Some lessons learned from U.S.
delivery systems include:
f Political will: Prevention and education efforts
must be embedded in the culture.
f Fighting stigma is a never-ending battle and must
be evaluated and re-evaluated on a continual basis.
f All efforts must be integrated into the broadest
community possible.
Other scale-up issues.  A wide range of other issues
were identified by one or more of the organizations.
These include the need to integrate HIV and TB
services and develop improved diagnostic tools for
TB/HIV co-infection; to develop treatment for chil-
dren; to strengthen nurse-based care; to address sexual
violence; and to develop rapid lab monitoring tools.
AFL-CIO stressed that the workplace is a common
place to initiate comprehensive ARV treatment pro-
grams if there is political will. The programs must
include national policies for workers rights and a focus
on building capacity of all business leaders.
“3 by 5” Campaign – World Health
Organization
Presentation by Nelle Temple Brown
WHO and UNAIDS recently launched a global
initiative to have three million people in developing
countries on antretroviral therapy by the end of 2005
(“3 by 5”).   The long-term goal of the initiative is to
achieve universal access to antiretroviral therapy
(ART) as a human right.  The “3 by 5” target origi-
nated with the 2001 United Nations General Assembly
Special Session on AIDS (UNGASS) target that stated
“we should be able to treat 50 percent of those who
need treatment (clinical AIDS, CD4 < 200) by 2005.”5
5 United Nations General Assembly, “Declaration of Commitment on HIV/AIDS,” 2001
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WHO’s strategy will be to catalyze rapid uptake of
ART in communities where it is needed now, but is not
widely accessible, by adopting a two-pronged ap-
proach of (1) supporting countries to recognize and
respond to the HIV/AIDS treatment gap and leverage
resources to enable ART to be scaled up rapidly in line
with the 3x5 target and (2) simplifying and standardiz-
ing ART as much as possible (without compromising
effectiveness) so it can be universally scaled up and
delivered in resource-constrained settings.
The initiative is being carried out on an emergency
basis and includes particular attention to coordinating
and streamlining WHO internal procedures.  The
WHO strategic framework includes five categories and
14 elements:
1. Global leadership, alliances and advocacy
(elements 1-4)
2. Urgent, sustained country support (elements 5-8)
3. Simplified, standardized tools for delivering
antiretroviral therapy (elements 9-11)
4. Effective, reliable supply of medicines and
diagnostics (element 12)
5. Rapidly identifying and reapplying new knowledge
and successes (elements 13-14)
Additional efforts of the initiative include ongoing
negotiation and coordination with WHO partners.
Budgets and workplans for 2004-2005 are in the
process of being approved, and financing is being
secured.  Milestones in the initiative will be reported
at the International AIDS Conference in Bangkok in
July 2004.
More information about the “3 by 5” Campaign is
available at www.who.Int/3by5.
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III.  Essential Elements of Scale-Up Strategy as
Outlined by Participants
The participants agreed that a scale-up strategy should
involve the following as key elements. They are
divided into program related issues and principles and
are in no particular order.
Program Issues
f Approaches must simplify, adapt and
decentralize treatment delivery. Any scale-up
strategy must support models that are simple,
adaptable, decentralized, and transparent. They
should also make use of existing capacity, entry
points for care and treatment, and funding streams.
The strategy should be driven by local needs and
local context. All minimum standards of care and
diagnostics must be reviewed and adapted for each
country setting. Fixed dose combinations have
proven to simplify treatment and improve
adherence and should be considered as key to
successful scale-up of ARV treatment.
f Community mobilization and PLHA
involvement must be a centerpiece of any scale-
up strategy. Community involvement must be
substantive and ensure full participation by civil
society organizations in the design, delivery and
evaluation of ARV treatment programs, especially
at the country level. Adequate resources must be
made available to support community mobilization
and PLHA involvement.  Resistance to
involvement of PLHAs and associations of PLHAs
must be addressed and overcome, and the rights of
PLHAs must be protected.  In addition to making
PLHA involvement a fundamental principle of its
own programs, the U.S. should be in the forefront
in supporting and facilitating PLHA involvement
in multilateral and country-level policies and
programs.
f Drug procurement should be competitive,
transparent, and non-corrupt.  Treatment
programs should support open competition
between generic and branded pharmaceutical
agents so that people have the right to procure
lifesaving AIDS medications at best world prices.
The strategy should provide full transparency in
drug procurement and should follow the World
Health Organization’s guidelines for antiretroviral
medicines. Efforts should be made to eliminate
drug sector corruption, including establishment of
an international drugs and commodities anti-
corruption program.
f U.S.-supported ARV treatment programs
should have a global reach.  The strategy should
provide for treatment beyond the focus countries of
the President’s Emergency Program (PEPFAR) to
include additional nations, such as India, where the
epidemic is spreading most quickly.
f ARV treatment programs must address barriers
to access as well as the multisectoral dimensions
of the epidemic.  The strategy for ARV treatment
scale-up should include measures to ensure that
potential barriers – such as violence, stigma and
discrimination – do not prevent access to
treatment, which begins with testing for HIV.
Design of testing and treatment programs should
include gender analysis, that is, analysis that
focuses on the way the epidemic affects men and
women differently as a result of society’s
expectations of their proper roles and
responsibilities. The strategy must ensure that
people receiving ART also have access to clean
water, a stable food supply, immunizations, and
antibiotics; all of this will help reduce basic
illnesses that lower overall quality of health.
Psychosocial support services are also needed.
There is an urgent need for resources and activities
related to HIV/TB co-infection.
f Operational ARV treatment-related research
and development must be supported.  A
successful scale-up strategy must involve a
research and development component that
examines such questions as fixed dose
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combination, minimum standards of care and
diagnostics, diagnostic tools, and pediatric
formulation. Specific needs and priorities for
operational research should be identified and
implemented.  Among those is a need for further
research to improve adherence and reduce toxicity.
Principles
f Human rights and equity concerns should be
fundamental in determining access to ARV
treatment.  Respect for human rights must be a
cornerstone of any strategy.  A scale-up strategy
should be women- and family-centered, include
measures to ensure non-discrimination, and remove
barriers to access for vulnerable populations.
Gender analysis and priority attention to ending
gender violence should be included and the
voluntary nature of testing should be safeguarded.
The strategy should also ensure equitable access to
other care services for PLHAs and those affected
by HIV/AIDS.  Equity considerations should help
guide decisions about resource allocation within
U.S. ARV treatment programs.
f Coordination within the U.S. government and
with other governments, civil society, and the
private sector should be a prerequisite for all
programs to increase impact and avoid
duplication.  Serious attention must be given to
ensuring coordination and coherence across U.S.
government global AIDS programs.  U.S.-
supported treatment programs should be
coordinated with other global strategies and
initiatives, as well as coordinated at the country
level.  The strategy should endorse a joint effort
amongst all governmental and civil society players,
particularly at the in-country level. It should
outline a concrete and credible plan for donor
coordination that includes mechanisms for
coherence among donors and for involving all key
stakeholders in country-level consultations.  The
strategy should identify remedies for countries
where structural adjustment programs interfere
with effective scale-up of ARV treatment.
f The strategy must ensure local ownership by
involving key stakeholders at the country level
in the design, implementation, and evaluation of
treatment policies and programs.  While
affirming an important role for a variety of sectors
and stakeholders, the public sector must be the
principal actor in ARV treatment programs overall
to reach the widest clientele.
f Steps to ensure the sustainability of programs
should be integral to all U.S.-supported
treatment programs.  Sustainability rests heavily
on training and infrastructure development.  The
strategy should ensure that local health providers
(nurses, midwives, traditional healers, etc.) are
utilized in ARV distribution in support of these
existing relationships within communities.  This
may include priority access to treatment for health
providers.  Community engagement in treatment
education and treatment support is critical to
ensuring sustainability, as is a major emphasis on
human capacity development and strengthening of
organizations.
f The measure of the success of expanded
treatment access should encompass more than
just the number of individuals receiving ARV
therapy.  Monitoring and evaluation efforts must
be driven by all key program elements and not only
by target numbers outlined in the strategy.
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IV. Conclusions
The consultation confirmed that providing ARV
treatment in resource-poor settings is feasible, com-
plex, and challenging.  The high rate of adherence in
the experiences to date is encouraging, and those
involved in the programs are able to identify what
works and what must be addressed to expand the
programs to treat the millions of people who still lack
access to ART.  All agree that attention to clinical
issues is critically important, but that a wider range of
concerns, including social issues, are also key to
successful scaling-up of programs.
Discussion among consultation participants identified
several key treatment-related concerns that require
more priority attention in government policies and
programs. These include integration of gender analy-
sis, HIV/AIDS-related stigma and discrimination,
guidelines for responding to co-infection of HIV/AIDS
and tuberculosis, and operations research.  Continued
advocacy is also needed to ensure that the U.S. fund-
ing commitments are fulfilled and sustained.
Disagreement between many advocates and
policymakers continues over a number of issues
related to scale-up of ARV treatment.  These include
disputes regarding application of trade policy related
to intellectual property rights, policies on HIV preven-
tion programs, and resource allocation for community
engagement and mobilization.
Several process concerns were also identified as
important to ensure effective policies and programs.
The government process for awarding grants needs to
be highly transparent.  To ensure local ownership and
sustainability of programs, mechanisms and proce-
dures are needed to ensure civil society involvement in
the design, implementation, and evaluation of strate-
gies and programs.  National treatment strategies,
where they exist, should serve as the basis for U.S.-
supported treatment programs.  A donor code of
conduct should be considered, which would establish
international standards for cooperation, collaboration,
and non-duplication of efforts by multiple donors.
Finally, the consultation affirmed the importance of
open and consistent dialogue among all parties—
government, civil society organizations (especially
PLHA groups) and the private sector—as an element
for effective policies and programs.  Advocates
recognized and fully support the need to increase
understanding of treatment issues within the global
AIDS advocacy community and to expand the circle of
those working to close the treatment gap and extend
the lives of millions of people who live where treat-
ment is not yet available.
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Glossary
ARV Antiretroviral drugs (ARV) inhibit the reproduction of retroviruses – viruses composed of
RNA rather than DNA. The best known of this group is HIV, human immunodeficiency virus,
the causative agent of AIDS.  http://www.ehendrick.org/healthy/000124.htm
ART Antiretroviral therapy.  A combination of antiretroviral drugs for treatment of HIV and AIDS.
3TC Lamivudine.  An antiretroviral drug, commonly used in combination with other drugs for
treatment of HIV.
CD4 count A count of the number of CD4-positive lymphocytes in the blood.
The most commonly used surrogate marker for assessing the state of the immune system. As
CD4 cell count declines, the risk of developing opportunistic infections increases. The
normal range for CD4 cell counts is 500 to 1500 per cubic millimeter of blood.
http://www.books.md/C/dic/CD4cellcount.php
d4T Stavudine. An anti-HIV treatment in the class of drugs called Nucleoside Reverse Tran-
scriptase Inhibitors (NRTIs). The body breaks down these drugs into chemicals that stop HIV
from infecting uninfected cells in the body, but they do not help cells that have already been
infected with the virus.  http://www.aegis.com/factshts/network/simple/stav.html
FDC Fixed-dose combination
NVP Nevirapine. An antiretroviral commonly used in combination with other antiretroviral drugs
to treat HIV.
Viral load The number of viral particles (usually HIV) in a sample of blood plasma. HIV viral load is
increasingly employed as a surrogate marker for disease progression.
http://www.books.md/V/dic/viralload.php
WHO
staging system
Stage I – Primary Infection
Stage II – Clinically Asymptomatic
Stage III – Symptomatic HIV infection
Stage IV – Progression from HIV to AIDS
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U.S. Strategy for Rapid Scale-Up of ARV Treatment:
Advocacy Issues and Concerns
Friday, December 12, 2003
9 a.m. to 5 p.m.
Methodist Building,
100 Maryland Avenue, N.E.
Washington, DC 20002
Key question: What are the essential elements of a viable U.S. strategy for rapid scale-up of ARV treatment that
must be included in the comprehensive, five-year U.S. global AIDS strategy that, under the new law, the Adminis-
tration must submit to Congress in February?
Agenda
9:00 Welcome, background, and introductions
9:20 Overview of the Status of the Strategy Development
Report on meeting with Ambassador Tobias and other Administration officials
9:45 Congressional Perspectives
What does Congress expect with regard to the strategy?  How will the strategy dovetail with the
election year legislative process?
Peter Smith, House International Relations Committee
10:30 Coffee Break
10:45 Potential Models of ARV delivery: strengths, weaknesses and concerns
Mandeep Dhaliwal, International HIV/AIDS Alliance
Tom Hardy, MTCT-Plus, Mailman School of Public Health, Columbia University
Mary Lyn Field, Family Health International
Rachel Cohen, Médicins Sans Frontières
Rob Lovelace, AFL-CIO
12:30 Lunch break (to be provided on-site)
1:00 Presentation on “3 by 5” Treatment Initiative
Nelle Temple Brown, External Relations Officer
World Health Organization
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2:00 Civil Society Recommendations on Essential Elements of a Viable Strategy to Meet Targets for
ARV Treatment
A discussion to identify, from the global AIDS advocacy community’s perspective, what essential
elements for effective ARV delivery must be included in the U.S. global AIDS strategy that is due
to be submitted to Congress in late February.   The discussion will also seek to identify how the
global AIDS advocacy community can best ensure that those elements are included in the strategy
and, by extension, in U.S. global AIDS policies and programs.
3: 45 Coffee
4:00 Dialogue with Dr. Joe O’Neill, Deputy Global AIDS Coordinator
A discussion about the essential elements of the strategy identified earlier in the day by the global
AIDS advocacy community.
5:00 Adjourn
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U.S. Strategy for Rapid Scale-Up of ARV Treatment:
Advocacy Issues and Concerns
December 12, 2003
Panelists
Rachel Cohen, U.S. Director
Campaign for Access to Essential Medicines
Médicins Sans Frontières
Dr. Mandeep Dhaliwal
Senior Programme Officer: Care & Support
International HIV/AIDS Alliance
Mary Lyn Field-Nguer, MSN
Associate Director, Treatment Planning and Support
Care and Treatment Division
Family Health International
Institute for HIV/AIDS
Tom Hardy
Associate Director
MTCT-Plus Secretariat
Mailman School of Public Health
Columbia University
Robert E. Lovelace
HIV/AIDS Program Coordinator
Solidarity Center, AFL-CIO
15
U.S. STRATEGY FOR RAPID SCALE-UP OF ARV TREATMENT
Appendix III
U.S. Strategy for Rapid Scale-Up of ARV Treatment:
Advocacy Issues and Concerns
Friday, December 12, 2003
Geeta Rao Gupta
International Center for Research on Women
Julie Hantman
HIV/AIDS Public Health Policy, Bioethics
David Haroz
UNAIDS
Ernest Hopkins
San Francisco AIDS Foundation
Zoe Hudson
Open Society Institute
Jodi Jacobson
CHANGE
Delisa James
NMAC
Sarah Kambou
International Center for Research on Women
Asma Lateef
Bread for the World
Rob Lovelace
American Center for International Solidarity
Daniel Malleborgina
Catholic Medical Mission Board (CMMB)
Hilary Marston
Gates Foundation
Marsha Martin
AIDS Action
Cheryl Morden
International Center for Research on Women
Priya Nanda
CHANGE
Participant List
Sherry Ayres
Africa Action
Gretchen Bachman
Family Health International
Kathleen Barnett
International Center for Research on Women
Sean Barry
Global Justice/Student Global AIDS Campaign (SGAC)
Bonnie B. Berry
International AIDS Trust
Paul Boneberg
Global AIDS Action Network
Heather Boonstra
AGI
Rachel Cohen
Médicins Sans Frontières
Helen Cornman
Consultant
Barbara de Zalduondo
Synergy Project
Mandeep  Dhaliwal
International HIV/AIDS  Alliance
Mary Lynn Field-Nguer
Family Health International
Janet Fleishman
Consultant
Eric A. Friedman
Physicians for Human Rights
Genevieve Grabman
CHANGE
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Mark Randolph
Program for Appropriate Technology in Health
(PATH)
Erik Rasmussen
Bread for the World
Asia Russell
Health GAP
Carl Schmid
AIDS Institute
Nelle Temple Brown
WHO
Ioanna Trilivas
International HIV/AIDS Alliance
Erin Tunney
Interaction
Angela Wakhweya
Save the Children
Paul Zeitz
Global AIDS Alliance
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